Novartis CEO warns that data on Covid-19 drugs is missing
Business was good for Novartis in the first quarter of the year.
Keystone / Georgios Kefalas
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
This content was published on
2 minutes
SDA-Keystone/ac
Español
es
Novartis: faltan datos sobre fármacos anticoronavirus
Clinical studies that are properly conducted are necessary to really determine the benefit of drugs, Narasimhan told the Reuters news agency on Tuesday. Only a few drugs had met the standards so far, he said.
The Swiss pharmaceutical company has initiated a clinical study with the anti-malarial drug hydroxychloroquine. Last month he told the Swiss media that pre-clinical studies in animals as well as the first data from clinical studies showed that hydroxychloroquine kills the coronavirus. While the therapy is not yet available, Narasimhan hinted that the first study results could be available in summer.
The Basel-based company also announced its first quarter results on Tuesday, reporting a 11% increase in net sales and a turnover of $12.28 billion (CHF12 billion). Novartis says it has managed to weather the coronavirus storm to keep production facilities going.
“Our operations and product demand remain very stable and strong. Mitigating actions helped to ensure minimal disruption to supply chain and ability to meet forward purchasing demand,” according to a company statement.
Forward purchasing and lower spending meant that Novartis made an extra $400 million due to the coronavirus pandemic in the first quarter. However, it is likely that these gains will be reversed over the remainder of 2020, the company cautioned.
More
More
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Is reforming the Swiss pension system still possible, and if so, how?
Solutions still need to be found to meet the challenge of an ageing population and to improve the pensions of low-paid workers, the majority of whom are women.
Job prospects remain good in Switzerland – apart from in Ticino
This content was published on
Employment prospects remain positive in Switzerland as a whole, but they are negative in southern Italian-speaking canton Ticino.
This content was published on
In an international comparison, Swiss adults perform above average in the basic skills of reading, everyday math and problem solving.
New carrier particle discovered for transporting drugs in body
This content was published on
Researchers at the federal technology institute ETH Zurich have discovered particles that can be used to deliver drugs precisely, for example to a cancerous tumour in the body.
Swiss parliament clears way for new start with e-ID
This content was published on
A new attempt to introduce electronic proof of identity has been made in Switzerland. The Senate has resolved the final differences in the legal provisions on a state e-ID.
Sixteen-day Swiss campaign against gender-based violence ends
This content was published on
The 16-day campaign against gender-based violence came to an end on Tuesday. Several hundred organizations mobilized across Switzerland during this period.
Swiss parliament wants CHF15 million for women’s Euro 2025
This content was published on
Parliament wants Switzerland to support next year's European Women's Football Championship with CHF15 million ($17 million).
Rare Roman coin auctioned for almost CHF2 million in Geneva
This content was published on
A rare Roman coin with a portrait of Brutus, the assassin of Julius Caesar, was sold at a Geneva auction on Monday for CHF1.89 million ($2.15 million), according to the organiser of the sale.
Swiss Senate approves federal budget without opposition
This content was published on
The Swiss army will receive an additional CHF530 million in 2025, and no cuts will be made to direct payments for agriculture. What is unclear is how much will be saved on foreign aid.
Swiss suspend decisions on asylum-seekers from Syria
This content was published on
Asylum procedures and decisions for asylum-seekers from Syria will be suspended with immediate effect until the situation can be reassessed, the State Secretariat for Migration (SEM) said.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.